All GLP-1 weight loss drugs articles
-
NewsThe Grocer launches Health Summit to tackle the future of food
The Grocer is launching the Health Summit as regulation, GLP‑1s and HFSS upheaval put wellbeing at the top of food and drink boardroom agenda
-
NewsSupreme profits boosted beyond expectations by vapes and Slimfast
The group, which supplies vapes, drinks, batteries, lighting and cleaning products, is set to report record results for the year to 31 March 2026
-
Analysis & FeaturesWho is worst hit as the UK buys less food & drink?
GLP-1 weight-loss drugs are only part of the story as data shows spend is down or in suppressed growth in multiple channels
-
Comment & OpinionImpact Makers podcast provides straight-talking scrutiny
Throughout, the podcast stays hyper-focused on why the subject at hand matters to brands
-
Analysis & FeaturesBritain’s Biggest Brands 2026: how healthy are the UK’s biggest brands?
Brits are turning away from UPFs and HFSS goods. But with definitions blurred, and indulgence still desired, it’s a mixed picture for food and drink
-
NewsChocolate sales rising faster among GLP-1 users, Lindt claims
According to Lindt, US sales of premium chocolate increased among GLP-1 users by nearly 17% in 2025
-
NewsWeight-loss drug users cut grocery and takeaway spending
Consumers using weight-loss drugs reported notable changes in their diets, scaling back on high-calorie convenience food and alcohol in favour of healthier options
-
Category ReportThe big dairy drink shake-up: trends in dairy drinks 2026
Dairy drinks makers are facing both the sugar tax and the rise of GLP-1 drugs. What are the challenges – and the opportunities?
-
NewsApplied Nutrition to open Knowsley distribution centre and HQ
The centre will support accelerating demand for Applied Nutrition’s products
-
Comment & Opinion‘Good intentions’ are not enough, food needs a fundamental reset
Professor Susan Jebb argues we have reached the ‘tipping point’ that signals doom for any company no longer prepared to get on board the health train
-
NewsComplete food industry ‘reset’ needed to tackle obesity crisis, says FSA chair
Professor Susan Jebb said she believed a ‘tipping point’ had been reached that meant companies would have to change direction if they were to survive
-
Comment & OpinionThe Hunger Game: Radio 4 series probes weight-loss jabs
Giles Yeo charts the early breakthroughs of the 1970s, before raising some pertinent questions
-
NewsBoots launches high street weight-loss jab service
Available in 17 stores across the UK, including in London, Manchester and Edinburgh, the service offers a private consultation with a pharmacist who can give treatment to eligible customers
-
NewsMyprotein partners with Greencore to launch food-to-go range
The range will include protein-enriched salads and wraps
-
Comment & OpinionFibre fix: why retail’s GLP‑1 obsession misses the real picture
In focusing on products designed for GLP-1 users, there’s a danger we overlook a much bigger, more fundamental issue: we all need to eat more fibre, says Jon Walsh, founder and CEO of Bio&Me
-
Analysis & FeaturesGLP-1s: Could they help make food more sustainable?
GLP-1 weight-loss drugs could be the hidden ally in the fight to make food more sustainable, with consumers set to eat less than ever before
-
Range PreviewSainsbury’s targets protein and appetite control with new own-label ranges
Sainsbury’s looks to ride the GLP-1 NPD wave with its latest push into high-protein and portion-controlled meals
-
Comment & OpinionGLP-1s will reshape food systems - but it’s all guesswork
No one wants to talk about the huge limitations in our knowledge of how GLP-1 agonists are likely to impact food choice, says Anthony Warner, development chef at New Food Innovation
-
NewsGousto creates ‘UK’s most addictive burger’ in UPF-ridden jab at fast food industry
You’ve tried Joe Wicks’ Killer protein bar, now taste Gousto’s terrible burger meal
-
NewsIGD launches GLP-1 insights programme for food businesses
The IGD Futures: GLP-1 programme will aim to help food industry businesses understand the threats and capitalise on the impacts of the drugs amid a huge rise in uptake